Partnership for Treatment Diagnosis for Chronic Diseases: QIAGEN weitet Anwendung von QIAstat-Dx op de Präzisionsmedizin aus

New Partnership is Performed with AstraZeneca on Oncology – an Electronic Complex Chronic Diseases // QIAGEN’s syndromic testing platform QIAstat-Dx is highly efficient, which can be used for patients in clinical phase since

Venlo, Netherlands, Aug. 28, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has enabled the processing of commercial transactions with AstraZeneca, proposing the processing and sale of diagnostic diagnostics for AstraZeneca’s future therapies for the treatment of chronic diseases.

In the framework of the association, QIAGEN introduced and validated a genotyping test for the syndromic test platform QIAstat-Dx. With these tests, the clinical and clinical routines can pass a genotyping of patients and patients and thus be separated quickly, by the genomic soul-oriented medicines of AstraZeneca for their own genomics are.

“A partnership with AstraZeneca is emerging with new disease ranges and together we are developing the first diagnostic analysis for chronic diseases on this platform,” said Fernando Beils, Senior Vice President and Head of Molecular Diagnostics at QIAGEN. “The development of the QIAstat Dx genotyping tests with AstraZeneca has leveraged QIAGEN’s expertise in the development and marketing of complementary diagnostics. Here you can find the best specific molecular testing platforms, a special clinical and commercial study of patient tests that you can perform.”

The QIAstat-Dx system is intended for the use of designed and used cost-efficient cards with all the necessary reagents and integrated probe studies. Mittels Multiplex Real-Time PCR recognizes and distinguishes more pathogens and generates results in another time. QIAstat-Dx can alleviate the Cycle Threshold (Ct) value and amplification technology, while there are also known sources, which are not available with endpoint PCR or other technologies. By the end of 2023, 4,000 instruments were completely flat.

QIAGEN is a pioneer in the medical sector and researches the pharmaceutical and biotechnology industry in the development of diagnostic diagnosis. These possible deviations and recognized problems are fun, a clinical treatment can lead to problems. QIAGEN has developed a unique technological spectrum – from the polymerase chain reaction (PCR) and the digital PCR (dPCR) with the Next-Generation-Sequencing (NGS). Today is the company in the field, products on the requests of its partner are combined.

QIAGEN has a new color palette with more than 30 years of experience in market research and analysis diagnosis – a knitting palette, the strength in the treatment meditation ermöglicht. The treatment is carried out with the selective profile of patients and patients, while tests are carried out with a diagnosis diagnosis. By using QIAGEN with Neuron23 and Helix together, there is a diagnosis diagnosis for the Krankheitsbereiche of the Oncology in the area.

About QIAGEN

QIAGEN NV, a Dutch holding company, is a prosperous company engaged in the recovery of molecular molecular research from biological research. QIAGEN research technology enables the processing and processing of DNA, RNA and proteins from blood, webs and other substances. Testing technology can perform this biomolecular analysis and analysis. Bioinformatics solutions and financial databases help to interpret data with more relevant and practically useful research. Automation integrations integrate these cost-effective and cost-efficient testing workflows. QIAGEN provides more than 500,000 people with the Range of Molecular Diagnostics (Health Research) and Life Sciences (academic research, pharmacological F&E and industrial applications, main research) for Verfügung. Zum June 30, 2024 beschäftigte QIAGEN weltweit more als 5,900 Mitarbeiter an über 35 Standorten. More information about QIAGEN can be found at http://www.qiagen.com.

Forward-looking statement

Einige der Angaben in dieser Pressemitteilung im Sinne von Section 27A of the US Securities Act (US-Wertpapergesetz) von 1933 in ergänzter Fassung and Section 21E of the US Securities Exchange Act (US-Börsengesetz) von 1934 in ergänzter Fassung als zkunftsgerichttete Aussagen (‘forward ‘-looking statements“) gilts. Be sure to report the most targeted products, including the responses to the COVID-19 pandemic, the Time Plan for Market Inführungen and Entwicklungen, regulatory Genehmigungen, financial and operational Forecasts, Wachstum, Expansionen, Kollaborationen, Market, Strategy or employed Somewhere authorized , but it is not limited to the fact that your experience is good for the net income and the results obtained. Your action is based on the basis of the current experiences and risks, which are associated with perhaps unsafe and risky risks. This is also the case: Risks in management and international business operations (einschließlich Auswirkungen von Währungsschwankungen und der Abhängigkeit von regulische sowie Logistikprozessen); Schwankungen der Betriebsergebnisse und je Verteilung auf unsere Kundengruppen; the market research for our products and knowledge in academic Research, Pharma, Testing and Molecular Diagnostics; Changes in our knowledge of our capabilities, our customers and our strategic partners, our knowledge and understanding of the environment, our technological progress, our knowledge of our quality and our QIAGEN products (einschließlich overall economics, quality and efficiency of our budgets and our budgets), that Möglichkeit, Die Regulatorische Zulassung voor our products die Schierigkeiten bei der Anpassung von QIAGENs Products an integrierte Lösungen und de Herstellung Solcher Produkte, die Fähigkeit des Unternehmens, nieuw Productideen zu entwickeln, umzusetzen and sich von den Products from wettbewerbers are available for the legalization of protection, market place of new products and the integration requirements of technology and technology; requirements of governments; global or regional economic developments; weather or transport conditions, care, natural disasters, political criticism or crises in the area of ​​security, a loss of the consequences and the duration of the COVID-19 pandemic and – 3 – your effects on the question of our products and other aspects of our country, or the higher authority; so whoever has the power, it is worth paying attention to the to come to market with the young or old Acquisitions, not who has made a real effort; and other Factors, look at the „Risk Factors“ in the Annual Report Form 20-F. Further information can be found in reports that QIAGEN has filed with the United States Securities and Exchange Commission (US-Börsenaufsichtsbehörde).

Source: QIAGEN NV
Category:Corporate

Contact QIAGEN: